562-02-003 ISMRM Abstract

Intratumoral Heterogeneity of DCE-MRI for Predicting Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer

Primary: Body - Breast

Secondary: Analysis Methods - Radiomics

562-02-003 · Breast MRI and the Role of AI · Wednesday, 13 May, 9:15 AM–10:10 AM · Digital Posters Row C

Keywords: Breast cancer Habitat radiomics DCE-MRI Pathological complete response Neoadjuvant Chemotherapy

Accepted

Wenjie Jiang ¹, Chen Bai¹, Xueying Zhao², Xinwei Tang¹, Xingke Huang¹, Xiaoying Li¹, Xiang Zhang¹, jun shen¹

¹Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,, Guangzhou, China

²MR Research, GE HealthCare, Beijing, China

Presenting Author: Wenjie Jiang

Synopsis

Motivation:

Goals:

Approach:

Results:

Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

References

1. Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 2021 May 1;39(13):1485-1505. doi: 10.1200/JCO.20.03399. Epub 2021 Jan 28. PMID: 33507815; PMCID: PMC8274745. [doi] [pmid]

2. I-SPY2 Trial Consortium; Yee D, DeMichele AM, Yau C, et al. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1355-1362. doi: 10.1001/jamaoncol.2020.2535. PMID: 32701140; PMCID: PMC7378873. [doi] [pmid]

3. Shi Z, Huang X, Cheng Z, et al. MRI-based Quantification of Intratumoral Heterogeneity for Predicting Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer. Radiology. 2023 Jul;308(1):e222830. doi: 10.1148/radiol.222830. Erratum in: Radiology. 2023 Jul;308(1):e239021. doi: 10.1148/radiol.239021. PMID: 37432083. [doi] [pmid]

4. McDonald KA, Kawaguchi T, Qi Q, et al. Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients. Ann Surg Oncol. 2019 Jul;26(7):2191-2199. doi: 10.1245/s10434-019-07338-3. Epub 2019 Apr 8. PMID: 30963401; PMCID: PMC6545241. [doi] [pmid]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/562-02-003